1 / 4

*Rachel A. McGovern, Art F.Y. Poon, Manuel Leal, Miguel Genebat,

Next Generation Deep Sequencing to Evaluate Viral Tropism in HIV-1 Patients Exposed to Maraviroc Add-On Therapy for 8 Days. *Rachel A. McGovern, Art F.Y. Poon, Manuel Leal, Miguel Genebat, Ezequiel Ruiz-Mateos, P. Richard Harrigan Poster #TUPDA0102. Background. X. X4. R5. Maraviroc.

magda
Download Presentation

*Rachel A. McGovern, Art F.Y. Poon, Manuel Leal, Miguel Genebat,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Next Generation Deep Sequencing to Evaluate Viral Tropism in HIV-1 Patients Exposed to Maraviroc Add-On Therapy for 8 Days *Rachel A. McGovern, Art F.Y. Poon, Manuel Leal, Miguel Genebat, Ezequiel Ruiz-Mateos, P. Richard Harrigan Poster #TUPDA0102

  2. Background X X4 R5 Maraviroc • The Maraviroc Clinical Test (MCT) evaluates virological response following 8 days of exposure to MVC add-on therapy • 27 MCT patients were followed longitudinally by 454 sequence analysis • Sequences were interpreted by Geno2Phenocoreceptor algorithm (3.5 FPR cutoff); >2% X4 virus was considered non-R5 • Analyses were conducted to identify any association between the degree of viral suppression and g2p score

  3. In those screened non-R5 by genotype MVC inhibited R5 virus, however the overall pVL remained fairly constant as non-R5 virus took over the population within 8 days. A) B) Screened R5 by deep sequencing Screened non-R5 by deep sequencing

  4. Maraviroc exposure in patients with non-R5 virus led to strong selection for virus with an extremely low FPR A) Screened non-R5 (3.4% X4) B) Relative Fitness in the Presence of Maraviroc 0.0 0.2 0.4 0.6 0.8 1.0 0 5 10 15 20 False Positive Rate In Summary patients with non-R5 virus, when exposed to short-term maraviroc add-on therapy, demonstrated a strong selection for X4 variants having extremely low g2P scores (0 ≤ FPR < 2) in as few as 8 days.

More Related